No abstract available.
Androgen-Insensitivity Syndrome* ; Male

No abstract available.
Androgen-Insensitivity Syndrome* ; Male

No abstract available.
Carcinoma, Small Cell* ; Female ; Ovary*

No abstract available.
Pregnancy* ; Uterine Hemorrhage*

No abstract available.
Female ; Lactation*

Progressive iris atrophy is a disease characterized by marked iris atrophy, iris hole, corneal endotherial abnormality, perripheral anterior synechia, and glaucoma. It is considered as a variant of iridocorneal endotherial syndrome with Chandler's syndrome and Cogan-Reese syndrome. We have experianced a 34 year old male patient complaning visual blurring in his left eye. At examination, we found characteristics of progressive iris atrophy. After filerring surgery, associated glaucoma was well controlled. Then we report a case with review of the literatures.
Adult ; Atrophy* ; Glaucoma ; Humans ; Iridocorneal Endothelial Syndrome ; Iris* ; Male

BACKGROUND: Fluid overload prior to continuous renal replacement therapy (CRRT) is an important prognostic factor. Thus, precise evaluation of fluid status is necessary to treat such patients. In this study, we investigated whether fluid assessment using bioelectrical impedance analysis (BIA) can predict outcomes in critically ill patients requiring CRRT. METHODS: A prospective observational study was performed in patients who were admitted to the intensive care unit and who required CRRT. BIA was conducted before CRRT; then, the ratio of extracellular water to total body water (ECW/TBW) was derived to estimate volume status. RESULTS: A total of 31 patients treated with CRRT were included. There were 18 men (58.1%), and the median age was 67 years (interquartile range, 51 to 78 years). Fourteen patients (45.2%) died within 28 days after CRRT initiation. Patients were divided into 16 with ECW/TBW ≥0.41 and 15 with ECW/TBW <0.41. Survival rate within 28 days was different between the two groups (P = 0.044). Cox regression analysis revealed a relationship between ECW/TBW ≥0.41 and 28-day mortality, but it was not statistically significant (hazard ratio, 3.0; 95% confidence interval, 0.9 to 9.8; P = 0.061). Lastly, the area under the curve of ECW/TBW for 28-day mortality was analyzed. The area under the curve of ECW/TBW was 0.73 (95% confidence interval, 0.54 to 0.92), and this was significant (P = 0.037). CONCLUSIONS: Fluid status can be assessed using BIA in critically ill patients requiring CRRT, and BIA can predict mortality. Further large trials are needed to confirm the usefulness of BIA in critically ill patients.
Body Water ; Critical Illness* ; Electric Impedance* ; Humans ; Intensive Care Units ; Male ; Mortality ; Observational Study* ; Prospective Studies* ; Renal Replacement Therapy* ; Survival Rate ; Water

No abstract available.
Blood Pressure* ; Child* ; Gwangju* ; Humans

No abstract available.
Fracture Fixation, Intramedullary*

PURPOSE: To represent our clinical experiences on the use of distally or proximally based sural artery pedicled flap for the treatment of soft tissue defects of the leg, ankle or foot. We expanded the indication for soft tissue coverage using sural artery flap by adding a proximally based sural artery flap to the distally based flap presented previously. MATERIALS AND METHODS: Since 1994, 55 patients with soft tissue defects of the leg, ankle and foot were covered by using sural artery pedicled flaps, proximally based flaps in 7 patients and distally based in 48 patients. The size of the flaps varied from 5 cm wide and 6 cm long to 10 cm wide and 15 cm long. RESULTS: All of the flaps except one survived. Marginal necrosis of the flap ocurred in 3 cases. Another three cases showed venous congestion during the early postoperative period. Sensibility loss was observed on the dorsolateral aspect of the foot. An unsightly scar was left at the donor site. CONCLUSION: The sural artery pedicled flap has a wide variety of indications, and can be used as a good alternative method for soft tissue coverage of small and medium sized soft tissue defects of the leg, ankle or foot. However, donor site morbidities should be considered before surgery.
Ankle* ; Arteries* ; Cicatrix ; Foot* ; Humans ; Hyperemia ; Leg* ; Necrosis ; Postoperative Period ; Surgical Flaps* ; Tissue Donors